Please check your internet connection and try again.
# كلونازيبام (Clonazepam)
## Overview
Clonazepam is a high-potency, long-acting benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor. It possesses anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnestic properties.
## Primary Indications
* **Seizure disorders:** Absence seizures, Lennox-Gastaut syndrome, and myoclonic seizures.
* **Panic disorder:** With or without agoraphobia.
* **Off-label:** Adjunctive treatment for acute mania, akathisia, or restless legs syndrome.
## Adult Dosing
* **Seizure Disorders:** Initial dose 0.5 mg orally 3 times daily. Increase by 0.5–1 mg every 3 days until seizures are controlled or side effects become limiting. Maintenance: 8–10 mg/day; maximum 20 mg/day.
* **Panic Disorder:** Initial dose 0.25 mg orally twice daily. Increase to target dose of 1 mg/day after 3 days. Maximum 4 mg/day.
## Pediatric Dosing
* **Seizure Disorders (Infants/Children up to 10 years or 30 kg):** Initial dose 0.01–0.03 mg/kg/day divided into 2–3 doses. Increase gradually by 0.25–0.5 mg every 3 days to a maintenance range of 0.1–0.2 mg/kg/day. Maximum dose not established; use clinical titration.
## Dose Adjustments
* **Hepatic Impairment:** Reduce dose in patients with mild-to-moderate impairment; contraindicated in severe liver disease (risk of hepatic encephalopathy).
* **Renal Impairment:** No standard adjustment required, but use caution due to the risk of accumulation of active metabolites.
* **Geriatrics:** Titrate slowly due to increased sensitivity to sedative effects and high risk of falls/cognitive impairment.
## Contraindications
* Hypersensitivity to clonazepam or other benzodiazepines.
* Significant liver disease.
* Acute narrow-angle glaucoma.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, dizziness, ataxia, fatigue, impaired coordination, and cognitive dysfunction.
* **Serious:** Respiratory depression (especially when co-administered with opioids), paradoxical reactions (aggression, irritability), and physical dependence leading to withdrawal syndrome upon abrupt cessation.
## Key Drug Interactions
* **Opioids:** Increased risk of profound sedation, respiratory depression, coma, and death (Black Box Warning).
* **CNS Depressants:** Alcohol, barbiturates, and other sedatives have additive depressant effects.
* **CYP3A4 Inhibitors:** May increase clonazepam serum concentrations.
* **Inducers:** Carbamazepine, phenytoin, and phenobarbital may decrease clonazepam levels.
## Monitoring
* Monitor for excessive sedation, coordination, and mood changes.
* Assess for misuse, abuse, or development of tolerance.
* Evaluate pulmonary function in patients with compromised respiratory systems.
## Clinical Pearls
* **Tapering:** Never discontinue abruptly due to risk of status epilepticus and severe withdrawal symptoms (seizures, psychosis). Taper slowly over weeks or months.
* **Fall Risk:** High risk in elderly populations; consider non-pharmacological alternatives for anxiety first.
* **Parenteral:** Intravenous administration is generally not recommended for status epilepticus compared to lorazepam or diazepam due to duration of onset and formulation availability.
***
*Disclaimer: This information is for educational purposes and does not replace medical judgment. Always verify current prescribing information, local institutional protocols, and patient-specific factors before administering any medication.*
